Company profile for Shanghai Shyndec Modern PharmaceuticalCo

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Shanghai Modern Pharmaceutical Co., Ltd. from Shanghai Institute of Pharmaceutical Industry as the main sponsor, the Joint National Engineering Research Center for Pharmaceutical Preparations, Shanghai Ruijin Hospital, Hiroji medical high-tech company's five co-sponsored enterprises and to market-oriented high-tech pharmaceutical companies. The company in 1997 was assessed as high-tech enterprises in Shanghai and has been ma...
Shanghai Modern Pharmaceutical Co., Ltd. from Shanghai Institute of Pharmaceutical Industry as the main sponsor, the Joint National Engineering Research Center for Pharmaceutical Preparations, Shanghai Ruijin Hospital, Hiroji medical high-tech company's five co-sponsored enterprises and to market-oriented high-tech pharmaceutical companies. The company in 1997 was assessed as high-tech enterprises in Shanghai and has been maintained so far, all the products and dosage forms all through the State Food and Drug Administration's GMP certification. June 16, 2004, Shanghai Modern Pharmaceutical Co., Ltd. A shares listed on the Shanghai Stock Exchange successfully issued, the securities code: 600.42 thousand, the securities referred to as: Modern pharmaceuticals. The company through the capital markets for the industrial operation and the best combination of capital operation, greatly forged and nurtured the company's core competencies and further strengthened the road of taking the technology industry's confidence. August 2004, the modern pharmaceutical business Qiu Hasen Henan Pharmaceutical Holdings Limited, and renamed the Shanghai Modern Hassan (Shangqiu) Pharmaceutical Co., Ltd., complement and expand the company's production capacity of water injection. In May 2008, the modern pharmaceutical acquisition of a wholly-owned Shanghai Pharmaceutical Co., Ltd. Medical Engineering Institute to form R & D, production and marketing functions as a whole, with chemical raw materials, pharmaceutical preparations and bio-pharmaceutical products, the new high-tech pharmaceutical enterprises, under the 5 subsidiaries and 3 production bases. The company's size and profitability in the pharmaceutical industry in Shanghai, the top 10% of the column, and enter the Top 100 list of China's pharmaceutical enterprises. Modern Pharmaceutical R & D center has been identified as Enterprise Technology Center in Shanghai, the company's R & D Center, Dr. 3, Master 16. The majority shareholder Shanghai Institute of Pharmaceutical Industry to have Chinese Academy of Engineering, two people, enjoy the special allowance of the State Council 68, National Center for Drug Evaluation Experts 12. Meanwhile, the Shanghai Pharmaceutical Industry Research Institute is an interdisciplinary doctorate in pharmacy to grant the right of units, has a pharmacy doctoral student in all disciplines, the field of training qualifications, and Shanghai Jiao Tong University build a "School of Pharmacy, Shanghai Jiao Tong University" to train master's and doctoral pharmaceutical field Health. In the Chinese Academy of Engineering led by a strong scientific research, management, production team, led by the modern pharmaceutical active part in the production process level and the engineering skills enhancement, edge highlighting, impressive: The modern pharmaceutical business is mainly engaged in domestic and the world's leading new types of pharmaceutical preparations, biological pharmaceuticals, chemical raw materials and Chinese medicine formulations of the R & D, production and sales. Currently has chemical raw materials, biological and chemical raw material medicine, microbial fermentation products and tablets, capsules, granules, injections, suspensions, suppositories, and ointments such as product formulations. In the new preparation area, full use of new slow-release technology platform, so that many traditional varieties of fresh with new vitality; in the field of bio-pharmaceuticals, by virtue of a high-quality, high-level R & D team, through the representative of the international most advanced level of biological separation and purification Technology has won the market, the products are exported to overseas; in the field of chemical raw materials, through the process technology continues to enhance its market share to stay ahead. Many products are included in the company's national "Ninth Five-Year" key scientific and technological projects, state-level torch plan project, the Shanghai Hi-tech achievement transformation project, the Shanghai Torch Program projects, and has repeatedly won the National Key New Product Award, Shanghai Science and Technology Achievement Award, Shanghai Excellent New Product Award, Shanghai and Shanghai Famous Brand famous quality products such as the pharmaceutical industry. The main products Azithromycin tablets, nifedipine controlled-release tablets, sustained-release capsules of cefalexin, cefaclor sustained-release capsule, enalapril maleate tablets, sustained-release suspension of dextromethorphan and azithromycin, zidovudine, Drospirenone, lipoic acid and other raw materials and other products have a high market share and visibility, best-selling overseas markets. "Modern" trademark in 2007 was "Shanghai famous brand" title. The main brand "Shenkar ®", "Shen Luo ®", "Xiaomei ®", "PU Yue Qi ®", "Pu Rainbow ®", "pleased ®", "PU Hui-Zhi ®", "excellent Xin Zhi ® "," supporting sling ® "," Pu Xiu ® "and so on, in the domestic market enjoy a high reputation. Shanghai Institute of Pharmaceutical Industry Group, established strategic goal is to become the leading high-tech pharmaceutical enterprise group, the modern pharmaceutical R & D as the group's own industrialization base for their own strategic goals have been identified, namely, research and innovation system formation and the Group of upstream and downstream co-operation process and to national "Eleventh Five-Year" special "Shanghai Modern Pharmaceutical Drug integrating innovative technology platform" and "the establishment of a process control of new drug formulations and process technology platform" as an opportunity to further enhance the results of scientific research and industrialization of their own transformation capacity, the formation of the modern pharmaceutical distinctive core competencies.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
Bldg.6 No.1320, Beijing West Road 200 040 Shanghai
Telephone
Telephone
+86 216 251 0759
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

CPhI China

Not Confirmed

envelop Contact Supplier

CPhI China

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]
Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets
With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

Impressions: 1138

https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

Radio Compass
06 May 2025

VLOG #PharmaReel

[Sponsored by another company]
This PharmaReel highlights Pfanstiehl's portfolio, featuring highest-purity, low-endotoxin injectable-grade excipients, generic APIs and intermediates, HPAPIs, and modified carbohydrates. The company provides API custom synthesis and ADC linker manufacturing services, all backed by USFDA certification.

Impressions: 348

read-more

DATA COMPILATION #PharmaFlow

[Sponsored by another company]
Excipient Market Overview: Roquette announces restructuring post IFF Pharma buyout; WHO, FDA advance regulatory frameworks
The pharmaceutical excipients market saw significant strategic consolidations, technological developments, and regulatory adaptations in 2025. Globally, the pharmaceutical excipients sector is growing at a compound annual growth rate of 6.6 percent, and was valued at US$ 8.85 billion in 2024. It is projected to reach US$ 14.77 billion by 2032.This year, the sector is witnessing technological advancements, regulatory evolution, and strategic business realignments. North America continues to dominate the global excipients landscape, with a 39.8 percent market share. The Asia-Pacific region is the fastest-growing segment with a substantial 30.4 percent market share, driven by increasing investments in pharmaceutical manufacturing, growing demand for cost-effective drugs, and rising healthcare expenditure across developing economies.Major excipient providers include BASF, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, DuPont, Evonik, Seqens, Actylis, SPI Pharma, PMC Isochem, Croda International, Pfanstiehl, Kewpie Corporation, Boai NKY Pharmaceuticals, ICE Pharma, Roquette, Nanjing Well Pharmaceutical, Minakem, Ashland Global, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)Roquette restructures after buying IFF Pharma; Colorcon partners ASHA CelluloseIn May, Roquette completed its acquisition of IFF Pharma Solutions. Valued at up to US$ 2.85 billion in enterprise value, this transaction represents a major consolidation in the pharmaceutical excipients market. The acquisition significantly enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide. Roquette announced a comprehensive, new organizational structure following the acquisition, indicating the company’s commitment to integrate IFF Pharma Solutions’ capabilities seamlessly into its existing operations. This consolidation creates a more robust platform for addressing the growing demand for specialized excipients in complex drug formulations, particularly as the industry moves towards more personalized approaches to medicines.So far, the year has also witnessed some strategic alliances, such as Colorcon’s partnership with ASHA Cellulose. As part of the deal, Colorcon will become the exclusive representative for two ASHA products — ASHACEL and ASHAKOTE — throughout Europe, the Middle East, Africa, Northeast Asia and Southeast Asia.Brenntag Specialties has announced an exclusive distribution agreement with MEGGLE Excipients to expand market reach. This collaboration makes available a broad portfolio of over 30 high-quality lactose-based excipients for various applications in the pharmaceutical industries across the Netherlands, Belgium, Norway, Finland, and Sweden.The portfolio’s versatility offers optimal solutions for a wide range of pharmaceutical applications, including tableting through both granulation and direct compression, powder preparations, and dry powder inhalation. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)WHO, FDA drive new standards with GMP guidelines; Pfanstiehl launches injectable-grade glycineIn March, the World Health Organization had put out a publication titled “Good Manufacturing Practices for Excipients used in Pharmaceutical Products.” WHO’s excipient GMP guideline emphasizes modern quality management principles, comprehensive risk assessment protocols, and supplier qualification procedures for excipients across all stages of production, storage, and distribution.Meanwhile, the US Food and Drug Administration (FDA) has proposed amendments to the Food, Drug, and Cosmetic Act as part of its FY 2025 legislative proposals, specifically targeting supply chain transparency for high-risk excipients. The FDA proposal would require certain excipients designated as high-risk to carry labeling that identifies the original manufacturer’s name and address. This initiative addresses what FDA has identified as a lack of transparency in excipient supply chains.In April, IFF Pharma Solutions launched Low Nitrite METHOCEL hydroxypropyl methylcellulose (HPMC). This innovative product is specifically designed to reduce the risk of nitrosamine formation in finished pharmaceutical dosages, addressing one of the most pressing concerns in contemporary pharmaceutical manufacturing.Pfanstiehl, a global leader in high-purity excipient manufacturing, announced the launch of its High Purity Low Endotoxin Low Metals (HPLE-LM) injectable-grade glycine. This multi-compendial glycine is specifically engineered for use in biologics, vaccines, and the downstream purification of monoclonal antibodies (mAbs). Manufactured under ICH-Q7 cGMP regulations at Pfanstiehl’s advanced facility in Waukegan, Illinois, the product meets stringent global pharmacopeial standards. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)Shin-Etsu Chemical invests in Japan, Germany to expand cellulose productionIn March, Shin-Etsu Chemical announced investments in pharmaceutical cellulose business operations in Japan and Europe, thereby showing significant commitment to market expansion. The company is making substantial investments at two key bases: the subsidiary SE Tylose GmbH in Germany, and the Naoetsu Plant in Joetsu, Japan. In Germany, a new production facility for the pharmaceutical excipient L-HPC will be built adjacent to the existing facility, creating a dual base with the Naoetsu Plant. The excipients market in 2025 has seen innovation in functional applications. Research on BENEO’s Palatinose as a bedtime drink shows that it improves aspects of sleep and represents an innovative approach to excipient functionality. Palatinose is a naturally sourced, smart carbohydrate that provides full carbohydrate energy in a more balanced way, thanks to its low-glycemic profile.Gangwal Healthcare, with its EXCiPACT-certified GMP facilities and a robust portfolio of co-processed excipients like ProBlend, Starlose, and Microlose, is actively contributing to the pharmaceutical industry’s demand for functional excipients. The company also offers cellulose-based excipients such as Solvostar (Sodium Starch Glycolate) and Sallyso (Croscarmellose Sodium), designed to improve tablet disintegration and drug release profiles in oral solid dosage forms.Evonik announced a partnership with South Korea–based CDMO ST Pharm to expand its RNA and nucleic acid delivery services. This collaboration enables Evonik to integrate customized nucleic acids from ST Pharm seamlessly with its lipid and lipid nanoparticle (LNP) development and fill-and-finish services. This streamlined approach means that pharmaceutical companies can reduce complexity and increase speed-to-market for nucleic acid therapeutics. View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)Our viewThe pharmaceutical excipients market in 2025 is being shaped by several key trends including the development of multifunctional excipients that can simultaneously improve solubility, bioavailability, and control drug release in increasingly complex formulations.Moreover, the expanding generic medicines market is creating demand for cost-effective, versatile excipients. The growing importance of biologics and biosimilars is driving innovation in specialized excipients designed to maintain the stability and efficacy of these complex therapeutic products throughout their lifecycle. And nanotechnology continues to enable advanced nano-excipients for enhanced drug delivery and efficacy.In addition to these trends, we also notice a shift towards natural and plant-based excipients that is driven by sustainability concerns and potential biocompatibility benefits. 

Impressions: 1633

https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks

#PharmaFlow by PHARMACOMPASS
29 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty